3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
6
Phase 3
5
Phase 1/2
3
Phase 4
2
Phase 1
2
Status
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
2
Myeloid
2
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Myeloproliferative Disorders
1
Bronchiolitis Obliterans Syndrome
1
Blast Crisis
1
Interventions
Zoledronic Acid
23
Bevacizumab
13
nilotinib
12
Docetaxel
12
Paclitaxel
11
Everolimus
11
Letrozole
10
Imatinib Mesylate
10
Capecitabine
10
Erlotinib Hydrochloride
9
Drug Therapy
9
Carboplatin
9
pegfilgrastim
8
enzalutamide
8
Trastuzumab
7
Oxycodone
7
Nivolumab
7
Imiquimod
7
Gemcitabine
7
Epoetin Alfa
7
icotinib
6
Rituximab
6
Prednisone
6
Pemetrexed
6
Oxaliplatin
6
Leuprolide
6
Fulvestrant
6
Diclofenac
6
Dexamethasone
6
Cisplatin
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 4
×
INDUSTRY
×
asciminib
×
Clear all
NCT04877522
2026-05-11
Asciminib Roll-over Study
Novartis
Phase 4
Recruiting
347 enrolled
NCT06427811
2026-04-17
ASC4INDIA
Novartis
Phase 4
Completed
85 enrolled